bluuebunny/crossref_metadata_2025_split huggingface dataset:
Abstract PO-015: Differences in level-of-service for telehealth visits as compared to in-office visits for cancer and hematology patients seen in practices within the ASCO PracticeNET learning network
Authors: Bourbeau Brian , Guharoy Mou , Grubbs Stephen , Garrett-Mayer Elizabeth , Olson Kevin , Schilsky Richard L. 
Published: December 2020

Abstract
Introduction: In response to the need for social distancing and infection prevention during the COVID-19 pandemic, there has been increased use of telehealth services to manage cancer and hematology patients. Throughout March and April of 2020, the Medicare and Medicaid programs expanded coverage of telehealth services, allowing cancer and hematology patients to receive certain telehealth services from their home during the public health emergency. We analyzed data from ASCO’s PracticeNET learning network to examine the reported level-of-service for telehealth services compared to standard in-office visits.
Methods: 20 practices submitted their billing data for analysis; practices were located in 14 states and ranged in size from 2 to 29 hematologists/oncologists. We analyzed a total of 33,435 established patient evaluation and management visits performed by hematologists/oncologists from March 15 to April 18, 2020. 3,062 (9.1%) visits were performed via telehealth and 30,373 were performed in a physician office or outpatient hospital department. The level-of-service of each visit was identified through the reported Current Procedure Terminology (CPT) code, where levels 1-5 correspond to CPT codes 99211-99215, respectively, and level 5 represents the highest complexity visit. Telehealth visits were identified through use of the modifiers 95, GQ, and GT, as appended to the applicable CPT code.
Results: The level-of-service distribution for telehealth-based visits was level 1 (1%), level 2 (4%), level 3 (35%), level 4 (50%), and level 5 (11%). This contrasted with in-office visits: level 1 (3%), level 2 (2%), level 3 (27%), level 4 (51%), and level 5 (18%). Differences were greatest in level 3 visits (35% vs. 27%) and level 5 visits (11% vs. 18%). Differences in level-of-service persisted when exploring various disease cohorts, including patients with solid neoplasms, blood neoplasms, benign hematology disorders, and circulatory disorders.
Conclusions: Analysis of established patient visits showed that telehealth visits were reported at lower level-of-service as compared to in-office visits. This finding may be related to directing straightforward visits to be performed via telehealth or due to limitations in using telehealth by patients with complex medical problems.
Citation Format: Brian Bourbeau, Mou Guharoy, Stephen Grubbs, Elizabeth Garrett-Mayer, Kevin Olson, Richard L. Schilsky. Differences in level-of-service for telehealth visits as compared to in-office visits for cancer and hematology patients seen in practices within the ASCO PracticeNET learning network [abstract]. In: Proceedings of the AACR Virtual Meeting: COVID-19 and Cancer; 2020 Jul 20-22. Philadelphia (PA): AACR; Clin Cancer Res 2020;26(18_Suppl):Abstract nr PO-015.
Abstract PO-022: Impact of COVID-19 pandemic on new patient and consult visits at 20 hematology/oncology practices in the ASCO PracticeNET learning network
Authors: Bourbeau Brian , Guharoy Mou , Garrett-Mayer Elizabeth , Grubbs Stephen , Unger Paul , McAneny Barbara , Schilsky Richard L. 
Published: December 2020

Abstract
Introduction: During March 2020, as the emergence of COVID-19 began to influence medical and social behaviors in the United States, oncology practices reported a disruption in normal referral and patient management patterns. Participants and staff of ASCO's PracticeNET learning network sought to explore and quantify the impact of this disruption through an analysis of patient activity at multiple hematology/oncology practices.
Methods: 20 practices submitted their billing data for analysis; practices were located in 14 states and ranged in size from 2 to 29 hematologists/oncologists. From this dataset we analyzed a total of 11,453 new patient and consult visits (Current Procedural Terminology codes 99201-99205, 99241-99245, 99251-99255, and 99341-99345) performed by hematologists/oncologists from February 9 to April 18, 2020. The number of visits performed from February 9 to March 14, 2020 was compared to visits performed from March 15 to April 18, 2020. A principal diagnosis was assigned to each visit following usual coding and billing practices.
Results: From February 9 to March 14, practices performed an average of 70.1 (median 55.5) new patient and consult visits per week. From March 15 to April 19, practices performed an average of 44.5 new patient and consult visits per week. The average decrease in visits among practices was 35% (95% confidence interval (CI): -42%, -29%). The decline in visits per practice ranged from -61% to -13%. New patient and consult visits for solid neoplasms decreased by an average of 22% (95% CI: -31%, -13%), visits for blood neoplasms decreased by an average of 36% (95% CI: -25%, -47%), and visits for benign hematology and circulatory disorders decreased by an average of 44% (95% CI: -53%, -34%).
Conclusions: Oncology practices experienced a decline in new patient and consult visits, first observed in the week of March 15. New patient and consult visits for blood neoplasms, benign hematology, and circulatory disorders experienced a greater decline than visits for solid neoplasms. The decrease in activity could be the result of prioritization of resources or changes in patient behavior in seeking care. Further study is necessary to quantify the impact of these findings on patient access and outcomes and to monitor recovery efforts.
Citation Format: Brian Bourbeau, Mou Guharoy, Elizabeth Garrett-Mayer, Stephen Grubbs, Paul Unger, Barbara McAneny, Richard L. Schilsky. Impact of COVID-19 pandemic on new patient and consult visits at 20 hematology/oncology practices in the ASCO PracticeNET learning network [abstract]. In: Proceedings of the AACR Virtual Meeting: COVID-19 and Cancer; 2020 Jul 20-22. Philadelphia (PA): AACR; Clin Cancer Res 2020;26(18_Suppl):Abstract nr PO-022.
Abstract PO-076: Training and information during COVID-19 pandemic: The masterpiece in young oncologists
Authors: Ranallo Nicoletta , Bastianelli Lucia , Merloni Filippo , Cantini Luca , Ricci Giulia , Ballatore Zelmira , Berardi Rossana 
Published: December 2020

Abstract
Background: The COVID-19 pandemic was a health emergency that required a rapid response by the Italian National Health System. Health care professionals needed to be properly trained and informed about their patients' procedures and proper management. During an emergency, the information must be exhaustive, clear, and timely to allow correct diagnostic and therapeutic continuity. It is also important that all health workers are promptly and homogeneously trained to guarantee the best treatment path even during the pandemic. Our survey aimed to investigate the level of information and training of health workers in oncology during the pandemic and, in particular, the difference in perception between operators under and over 35 years of age.
Materials and Methods: An on-line multiple-choice survey was submitted to oncology health workers during the pandemic, investigating individual perception of resources, information, and staff training management by hospital centers. No open questions were included.
Results: A total of 383 health workers replied to the survey (116 under 35 years versus 267 over 35 years). In the under-35 group, a total of 65% declared they had been timely and sufficiently informed to understand the extent of the problem compared to 50% of those over 35 (P=0.007). About 80% of young professionals were adequately informed and two thirds (63%) were informed about procedures/recommendations to be followed during the pandemic. However, in professionals over 35, only 56% declared they had the right information and over 65% did not feel adequately trained (P= &lt;0.01). Furthermore, 44% of those over 35 felt not sufficiently prepared for the management of the cancer patient during an epidemic compared to only 28% of those under 35 (P=0.015).
Conclusion: The survey showed a different perception of information and training of health care professionals based on the age group. This could be determined by a different degree of task and responsibility but also by the greater and faster readiness of the younger operators to acquire new information and to draw on a renewed ability to face an emergency by reorganizing themselves quickly and actively.
Citation Format: Nicoletta Ranallo, Lucia Bastianelli, Filippo Merloni, Luca Cantini, Giulia Ricci, Zelmira Ballatore, Rossana Berardi. Training and information during COVID-19 pandemic: The masterpiece in young oncologists [abstract]. In: Proceedings of the AACR Virtual Meeting: COVID-19 and Cancer; 2020 Jul 20-22. Philadelphia (PA): AACR; Clin Cancer Res 2020;26(18_Suppl):Abstract nr PO-076.
Abstract PO-083: Prostate cancer and COVID-19: Impact of hormonal therapy on severe outcomes
Authors: Tawagi Karine , Burton Jeff , Maslov Diana , Lunski Michael , Matrana Marc , Johnson Daniel 
Published: December 2020

Abstract
Background: Early reports on cancer patients infected with COVID-19 have suggested a high risk of hospitalization and death compared to the general population. Limited data are available on outcomes in specific cancer types. We aim to identify whether hormonal treatment impacts severe outcomes (rate of hospitalization, ICU admission, intubation, and death) in prostate cancer patients.
Methods: We conducted a multicenter study in the state of Louisiana, throughout the Ochsner Health System, in both tertiary and nontertiary centers. Patients must carry a diagnosis of prostate cancer and have a completed SARS-CoV-2 test between March 1st and April 30th, 2020. Chi-squared and Fisher’s exact tests were performed to compare the proportion of patients experiencing severe outcomes between treatment groups.
Results: As of April 30, 2020, a total of 56 patients with prostate cancer who had a positive SARS-COV-2 test were identified. Median age 69, median BMI 28.8, 78.6% (n=44) black, 58.9% (n=33) current/former smokers, HTN, DM2, and CKD were the most common comorbidities, and 12.5% (n=7) of patients had stage IV disease. Of these patients, 26.8% (n=15) were on hormonal treatment (received within 90 days of COVID+ test). In terms of severe outcomes, 58.9% (n=33) of patients required hospitalization, 17.9% (n=10) required ICU admission with 14.3% (n=8) patients requiring intubation, and 23.2% (n=13) of patients died. There was no statistical difference in rate of severe outcomes (rate of hospitalization, ICU admission, intubation, and death) among prostate cancer patients receiving hormonal therapy vs. those receiving no hormonal therapy.
Conclusion: With an ongoing global pandemic of COVID-19, it is important to identify characteristics leading to increased risk of severe events in cohorts of cancer patients. This small cohort does not identify hormonal therapy as a risk factor for increased rate of severe outcomes in patients with prostate cancer. Further analyses describing impact of specific hormonal regimens on risk of hospitalization and death will be completed by time of presentation.
Citation Format: Karine Tawagi, Jeff Burton, Diana Maslov, Michael Lunski, Marc Matrana, Daniel Johnson. Prostate cancer and COVID-19: Impact of hormonal therapy on severe outcomes [abstract]. In: Proceedings of the AACR Virtual Meeting: COVID-19 and Cancer; 2020 Jul 20-22. Philadelphia (PA): AACR; Clin Cancer Res 2020;26(18_Suppl):Abstract nr PO-083.
Abstract IA03: Optimizing immunostimulatory antibodies for cancer immunotherapy
Authors: Yu Xiaojie , White Anne , Glennie Martin , Tews Ivo , Fisher Hayden , Orr Chris , French Ruth , Beers Stephen , Al'Shamkhani Aymen , Dadas Osman , Roghanian Ali , Willoughby Jane , Cragg Mark S. 
Published: December 2020

Abstract
Agonistic antibodies directed to immunostimulatory receptors are a currently untapped source for immunotherapy. Whereas checkpoint blockers have translated into the clinic, the rules for agonistic antibodies have been more difficult to discern and these reagents await further optimization. Here we discuss the salient properties of monoclonal antibodies (mAb) required to strongly agonize these receptors and discuss potential strategies for the future. We show that immunostimulatory mAb (ISA) can agonize key stimulatory receptors on the cell surface—many of which are from the TNFR family—and highlight the importance of isotype. Using CD40 mAb as a paradigm, we show that receptor clustering is key for ISA responses—probably mimicking ligand. This clustering can be achieved via Fc gamma receptor (FcgR) engagement or independently with the hIgG2(B) isotype. For CD40 this is highly epitope dependent, showing that epitope, isotype, and domain location all interact to drive mAb agonism. Finally, we show that isotype engineering can overcome “weak” epitopes. This can be completely independent of FcgR interaction in the case of hIgG2B, which may be of use in humans where the FcgR profile within the tumor microenvironment may vary.
Citation Format: Xiaojie Yu, Anne White, Martin Glennie, Ivo Tews, Hayden Fisher, Chris Orr, Ruth French, Stephen Beers, Aymen Al'Shamkhani, Osman Dadas, Ali Roghanian, Jane Willoughby, Mark S. Cragg. Optimizing immunostimulatory antibodies for cancer immunotherapy [abstract]. In: Proceedings of the AACR Virtual Meeting: Advances in Malignant Lymphoma; 2020 Aug 17-19. Philadelphia (PA): AACR; Blood Cancer Discov 2020;1(3_Suppl):Abstract nr IA03.
Abstract IA11: AYA lymphomas: Bridging the divide
Authors: Kelly Kara 
Published: December 2020

Abstract
Lymphomas account for approximately 20-25% of annual cancer diagnoses in the adolescent and young adult (AYA) population, defined as ages 15–39 years. Despite continued improvements in lymphoma outcomes, AYAs have not exhibited survival gains to the same extent as other age groups. At present, this survival gap is a manifestation of many compounding factors including a lack of sufficient understanding of the tumor biology or the optimal therapeutic approaches, as well as delays in diagnosis, the supportive care needs, long-term toxicity risk, developmental stage of the AYA, and socioeconomic factors. There is no established standard of care for AYA lymphomas, and there is significant divergence in treatment approaches between medical and pediatric oncology.
Data on the heterogeneity of lymphoid malignancies in the AYA population as compared with younger pediatric and older adult groups will be reviewed. The highest proportion (35-70%) of lymphoid malignancies are due to Hodgkin lymphoma and lymphoblastic leukemia/lymphoma, followed by diffuse large B-cell lymphoma (10%-20%). Sex, race, and ethnic differences in the AYA lymphomas are also observed. These findings suggest that AYA lymphomas are biologically distinct from those present in the pediatric and adult populations. Factors that may contribute to the observed age-based variation in disease include evolution of the immune system with age, changes in the impact of genetic susceptibility, and viral and/or environmental exposures.
There is a marked difference between the pediatric and adult approaches for AYA lymphomas. The example of AYA Hodgkin lymphoma will be reviewed. The pediatric backbone chemotherapy regimen has been doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide (ABVE-PC), whereas the adult regimen has been doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD). Radiation therapy is incorporated more often in pediatric high-risk regimens and adult low-risk approaches. Because disease biology does not conform to an 18-year-old cutoff, which of these approaches is most appropriate for AYAs has not been established. Treatment approach is not standard and is often driven by the experience of the physician. Recent progress in developing collaborative clinical trials through the North American National Clinical Trials Network will be reviewed.
Citation Format: Kara Kelly. AYA lymphomas: Bridging the divide [abstract]. In: Proceedings of the AACR Virtual Meeting: Advances in Malignant Lymphoma; 2020 Aug 17-19. Philadelphia (PA): AACR; Blood Cancer Discov 2020;1(3_Suppl):Abstract nr IA11.
Abstract IA25: CREBBP: Not all mutations are created equal
Authors: Green Michael R. 
Published: December 2020

Abstract
Follicular lymphoma (FL) and the EZB/C3 subtype of diffuse large B-cell lymphoma (DLBCL) are characterized by frequent mutations of chromatin-modifying genes, including KMT2D, CREBBP, and EZH2. Genomic analysis of serial biopsies from FL patients has allowed the reconstruction of evolutionary phylogenies and highlighted CREBBP mutations as occurring predominantly as early events in disease evolution and residing within common progenitor cells that seed relapse. Patient tumor cells with CREBBP mutations have significantly reduced MHC class II expression and perturbed T-cell responses to tumor, suggesting a role for CREBBP mutations in driving immune evasion. Knock-out and knock-down studies of Crebbp confirmed its tumor-suppressor function in animal models, but uncovered some differences compared to the phenotypes observed in association with CREBBP mutations in primary tumors. Mutations of CREBBP most often encode missense amino acid substitutions within the catalytic lysine acetyltransferase (KAT) domain rather than nonsense/frameshift variants that result in a loss of protein expression. Here I will discuss recently published and unpublished data regarding the function of CREBBP mutations in B-cell lymphoma, functional differences between classes of mutations (KAT domain missense vs. nonsense/frameshift) and between different mutational hotspots within the KAT domain. Furthermore, I will discuss how these functional insights provide a rationale for targeted therapeutic strategies in B-cell lymphoma.
Citation Format: Michael R. Green. CREBBP: Not all mutations are created equal [abstract]. In: Proceedings of the AACR Virtual Meeting: Advances in Malignant Lymphoma; 2020 Aug 17-19. Philadelphia (PA): AACR; Blood Cancer Discov 2020;1(3_Suppl):Abstract nr IA25.
Abstract PO-12: Activity of ASTX660, a small-molecule IAP antagonist, reveals a novel, immune-based therapeutic approach in T-cell lymphoma
Authors: Jueliger Simone , Ferrari Nicola , Ward George , Munck Joanne , Smyth Tomoko , Davis Matthew , Gewinner Christina , Ferraldeschi Roberta , Lyons John , Sims Martin 
Published: December 2020

Abstract
Introduction: ASTX660 is a potent, non-peptidomimetic antagonist of the cellular and X-linked inhibitors of apoptosis proteins (cIAP1/2 and XIAP), which is currently being tested in a first-in-human phase I-II study in patients with advanced solid tumors and lymphomas (NCT02503423). IAP antagonists are known regulators of cell death and have been reported to modulate immune responses (1). Herein, we describe the profile of ASTX660 in preclinical models with a specific focus on ASTX660's ability to harness a particular form of regulated cell death in T-cell lymphoma that directs an effective immune response and leads to sustained tumor regressions.
Methods: ASTX660 was profiled across a panel of T-cell lymphoma lines, assessing apoptosis, necroptosis, and immunogenic cell death (ICD). ASTX660 was tested in vitro with or without caspase-8/RIPK1 inhibitors to demonstrate mechanism of action. Target engagement along with induction of apoptosis, necroptosis, and ICD markers were analyzed by Western blotting and flow cytometry. Murine tumor models in immunocompetent and immunocompromised mice were utilized to evaluate the efficacy of ASTX660 in the presence or absence of an adaptive immune response.
Results: ASTX660 antagonized IAPs in cell lines, as indicated by a decrease in cIAP1 protein levels. In certain murine T-cell lymphoma cell lines, ASTX660 treatment was associated with an increase in cell death and release of biomarkers of ICD. Use of caspase and RIPK1 inhibitors indicated the cell death was via necroptosis. In a syngeneic model of T-cell lymphoma, administration of ASTX660 resulted in complete and sustained tumor regressions which were not seen in mice deficient in T and B cells. Mice cured of T-cell lymphoma by ASTX660 were resistant to a second inoculation of the same lymphoma.
Conclusion: These data add to the description of ASTX660's mode of action and our ongoing understanding of the preliminary clinical efficacy in T-cell lymphoma (2). We describe a new role for ASTX660 as an immunomodulatory molecule with potential to deliver a novel immune-based therapeutic approach in T-cell lymphoma.
References: 1. Michie J et al. Cells 2020;9(1). 2. Hollebecque A et al. 2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
Citation Format: Simone Jueliger, Nicola Ferrari, George Ward, Joanne Munck, Tomoko Smyth, Matthew Davis, Christina Gewinner, Roberta Ferraldeschi, John Lyons, Martin Sims. Activity of ASTX660, a small-molecule IAP antagonist, reveals a novel, immune-based therapeutic approach in T-cell lymphoma [abstract]. In: Proceedings of the AACR Virtual Meeting: Advances in Malignant Lymphoma; 2020 Aug 17-19. Philadelphia (PA): AACR; Blood Cancer Discov 2020;1(3_Suppl):Abstract nr PO-12.